Invex Therapeutics (ASX:IXC) reported Friday a loss of AU$0.0047 per diluted share for the half year ended Dec. 31, 2024, compared with a loss of AU$0.0281 per diluted share a year earlier.
The company's attributable loss after tax narrowed 83% to AU$356,535 from AU$2.1 million in the year-ago period, the filing said.
The biopharmaceutical company did not declare a dividend during the reported period.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。